IFNβ therapy in RRMS patients (n = 23) was associated with increased proportions of TB and NB cells, and a reciprocal reduction of UMB, SMB, and DN cells (Fig. 3a), in line with previous studies describing an effect of this cytokine on the redistribution of B cell subsets in MS patients [12]. This evidence concerns the gene IFNB1 and myeloid sarcoma.